NCT02019758View on ClinicalTrials.gov

Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

PHASE4CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

April 30, 2019

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

Oral Viscous Budesonide

Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily

DRUG

Fluticasone MDI

Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)

DRUG

Placebo slurry

Slurry of sucralose - 4 mL twice daily

DRUG

Placebo inhaler

Placebo inhaler - 4 puffs twice daily

Trial Locations (1)

27599

University of North Carolina, Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT02019758 - Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis | Biotech Hunter | Biotech Hunter